[Chemotherapy of gastrointestinal carcinomas and non-small-cell pulmonary carcinoma: a controversy].
Patients with metastatic gastrointestinal cancers and metastatic non-small cell lung cancer present an important challenge in medical oncology and palliative care. Symptoms caused by tumor progression should undoubtedly be treated. The management of asymptomatic patients, however, is still controversial. A clinical decision on whether an asymptomatic patient should be treated with chemotherapy at an early or at a late stage in the evolution of the disease must often be reached on an individual basis. Ongoing clinical research to improve treatment results is still urgently needed. Research programs should aim at (a) evaluating new drugs and (b) testing new multi-modal treatment strategies.
Fey
M F
MF
Institut für Medizinische Onkologie, Inselspital Bern.
Sauter
C
C
Alberto
P
P
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D003110:Colonic Neoplasms / Q000473:pathology / Q000601:surgery; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D010166:Palliative Care
D000970:Antineoplastic Agents
Chemotherapie gastrointestinaler Karzinome und nicht-kleinzelliger Lungenkarzinome: eine Kontroverse.